BioSpace News Archive

Cybin Inc. today announced that the United States Patent and Trademark Office has issued two patent grants that offer protection for its deuterated N, N-dimethyltryptamine (“DMT”) program.

Curium, a world leader in nuclear medicine, and PIUR IMAGING announced today a strategic partnership to advance thyroid diagnostics in Germany.

Reneo Pharmaceuticals, Inc. today announced the company will present a poster titled “Selective peroxisome proliferator-activated receptor (PPAR) delta (δ) agonist, mavodelpar, improves cellular bioenergetics in fibroblasts from patients with mitochondrial complex I deficiency” at the following upcoming scientific meetings.

Appili Therapeutics Inc. today announced that the company secured a commitment for the second stage of funding for ATI-1701 from the U.S. Air Force Academy (“USAFA”), who is working in partnership with the Defense Threat Reduction Agency (“DTRA”), the funding agency.

Larkspur Biosciences announced that data supporting development of a novel investigational therapy targeting Pin1 will be featured in a poster presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2023) on November 3 in San Diego, CA.

Fate Therapeutics, Inc. today announced that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2023 at 5:00 PM ET to report its third quarter 2023.

Phathom Pharmaceuticals, Inc. announced today that members of its management team are scheduled to participate in the following investor conferences in November.

Centessa Pharmaceuticals plc today announced a robust set of new preclinical data from in vivo and in vitro studies of its investigational, novel orexin receptor 2 (OX2R) agonist, ORX750, that support its potential best-in-class profile for the treatment of narcolepsy and other sleep-wake disorders.

Korro Bio, Inc. announced on July 14, 2023, the proposed business combination with Frequency Therapeutics, Inc., a publicly listed company, and its concurrent financing of approximately $117 million before expenses with leading healthcare specialist investors, which is expected to close immediately prior to completion of the merger.

Tisento Therapeutics today announced the initiation of a patient interview study to identify and describe the signs, symptoms, and health-related quality-of-life impacts of MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes) that are most burdensome to adults and adolescents living with this rare mitochondrial disease.